Ascletis Pharma advances its obesity pipeline with an FDA IND submission for ASC30_39 FDC, an oral combination therapy leveraging the company's proprietary small molecule GLP-1 and amylin receptor agonists.
An IND submission for ASC30_39 FDC is an early pipeline milestone based on preclinical and dog pharmacokinetic data, not a regulatory approval, trial result or guidance change. The company's lead asset ASC30 remains in Phase III with topline data not expected until Q3 2028, so this news does not materially change the investment outlook near term.
Ascletis Pharma has submitted an Investigational New Drug application to the U.S. FDA for ASC30_39 FDC, a once-daily oral fixed-dose combination targeting obesity. The candidate pairs the GLP-1R agonist ASC30 with the selective amylin receptor agonist ASC39, marking the first co-formulation of its kind to reach this regulatory stage.
No. An IND submission only allows clinical testing to begin. The lead drug ASC30 is in Phase III trials, with topline data not expected until the third quarter of 2028.